Nancy A. Grygiel - 20 Nov 2025 Form 4 Insider Report for AMGEN INC (AMGN)

Role
SVP & CCO
Signature
/s/ Nancy A. Grygiel
Issuer symbol
AMGN
Transactions as of
20 Nov 2025
Net transactions value
-$525,976
Form type
4
Filing time
21 Nov 2025, 20:34:41 UTC
Previous filing
22 Aug 2025
Next filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Grygiel Nancy A. SVP & CCO ONE AMGEN CENTER DRIVE, THOUSAND OAKS /s/ Nancy A. Grygiel 20 Nov 2025 0001816414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Options Exercise $266,190 +1,500 +21% $177.46 8,725 20 Nov 2025 Direct
transaction AMGN Common Stock Sale $505,894 -1,500 -17% $337.26 7,225 20 Nov 2025 Direct F1
transaction AMGN Common Stock Options Exercise $266,501 +1,639 +23% $162.60 8,864 20 Nov 2025 Direct
transaction AMGN Common Stock Sale $552,773 -1,639 -18% $337.26 7,225 20 Nov 2025 Direct F1, F2
holding AMGN Common Stock 105 20 Nov 2025 401(k) Plan F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Options Exercise $0 -1,500 -43% $0.000000 1,970 20 Nov 2025 Common Stock 1,500 $177.46 Direct
transaction AMGN Nqso (Right to Buy) Options Exercise $0 -1,639 -100% $0.000000 0 20 Nov 2025 Common Stock 1,639 $162.60 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F2 These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F3 These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.